Research programme: ORAI1 protein modulators - QUE OncologyAlternative Names: Q-202
Latest Information Update: 07 Jun 2016
At a glance
- Originator QUE Oncology
- Mechanism of Action ORAI1 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer
Most Recent Events
- 07 Jun 2016 Early research in Breast cancer in USA (unspecified route) before June 2016